SpringWorks Therapeutics (SWTX) News Today $47.21 -1.30 (-2.68%) Closing price 04:00 PM EasternExtended Trading$47.38 +0.17 (+0.37%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 2.5% - Here's What HappenedSpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 2.5% - Time to Sell?March 25 at 1:09 PM | marketbeat.comTraders Buy Large Volume of SpringWorks Therapeutics Call Options (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors purchased 12,381 call options on the stock. This represents an increase of 105% compared to the typical volume of 6,048 call options.March 22 at 1:59 PM | marketbeat.comRaymond James Financial Inc. Takes $10.53 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Raymond James Financial Inc. purchased a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 291,356 shares of theMarch 21, 2025 | marketbeat.comThis Is What Whales Are Betting On SpringWorks TherapeuticsMarch 20, 2025 | nasdaq.comPlatinum Investment Management Ltd. Invests $1.69 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Platinum Investment Management Ltd. bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,895 shares of the companyMarch 20, 2025 | marketbeat.com4SWTX : This Is What Whales Are Betting On SpringWorks TherapeuticsMarch 18, 2025 | benzinga.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 4.8% - What's Next?SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Down 4.8% - Here's WhyMarch 18, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Short Interest Down 22.0% in FebruarySpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 7,110,000 shares, a decrease of 22.0% from the February 13th total of 9,110,000 shares. Approximately 10.3% of the company's stock are short sold. Based on an average daily trading volume, of 2,210,000 shares, the days-to-cover ratio is presently 3.2 days.March 18, 2025 | marketbeat.comBank of New York Mellon Corp Trims Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Bank of New York Mellon Corp reduced its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 195,942 shares ofMarch 16, 2025 | marketbeat.comSpringWorks Shares Rise More Than 30% in 3 Months: Here's WhyMarch 12, 2025 | msn.comPeninsula biotech raises $35 million, looks to move quickly into late-stage mesothelioma trialMarch 12, 2025 | bizjournals.comVictory Capital Management Inc. Reduces Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Victory Capital Management Inc. cut its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 614,923March 12, 2025 | marketbeat.comSpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A BuzzMarch 11, 2025 | seekingalpha.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Candriam S.C.A.Candriam S.C.A. cut its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 80.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 164,015 shares of the company's stock after selling 681,155 shares during the peMarch 8, 2025 | marketbeat.comCheck Out What Whales Are Doing With SWTXMarch 7, 2025 | benzinga.comSpringWorks Therapeutics (NASDAQ:SWTX) Sees Unusually-High Trading Volume - What's Next?SpringWorks Therapeutics (NASDAQ:SWTX) Sees Strong Trading Volume - Time to Buy?March 7, 2025 | marketbeat.comStock Traders Purchase High Volume of Call Options on SpringWorks Therapeutics (NASDAQ:SWTX)SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors bought 13,068 call options on the stock. This is an increase of approximately 223% compared to the average daily volume of 4,050 call options.March 7, 2025 | marketbeat.comBadreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now owns 169,712 shares in the company, valued at $9,203,481.76. This represents a 10.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 6, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 49,000 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the transaction, the chief executive officer now owns 954,869 shares in the company, valued at approximately $51,792,094.56. The trade was a 4.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.March 6, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells 20,000 Shares of StockMarch 6, 2025 | insidertrades.comInvestors push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% lower this week, company's increasing losses might be to blameMarch 5, 2025 | finance.yahoo.comWhy SpringWorks Therapeutics (SWTX) Is Skyrocketing So Far in 2025March 4, 2025 | msn.comSpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6% - Here's What HappenedSpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6% - Here's What HappenedMarch 4, 2025 | marketbeat.comShort Interest in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Decreases By 36.7%SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) was the target of a large drop in short interest in February. As of February 15th, there was short interest totalling 9,110,000 shares, a drop of 36.7% from the January 31st total of 14,400,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the short-interest ratio is presently 4.6 days.March 2, 2025 | marketbeat.comIs SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now?March 1, 2025 | msn.comSpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up - Should You Buy?SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap Up - Should You Buy?March 1, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Bought by Los Angeles Capital Management LLCLos Angeles Capital Management LLC grew its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 30.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,760 shares of the company'sFebruary 28, 2025 | marketbeat.comSpringWorks Therapeutics (SWTX): Among the Best Performing Mid Cap Stocks to Buy According to AnalystsFebruary 26, 2025 | msn.comSpringWorks Therapeutics (SWTX): Among the Best Performing Mid Cap Stocks to Buy According to AnalystsFebruary 26, 2025 | msn.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Insider Bhavesh Ashar Sells 1,016 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $61.19, for a total transaction of $62,169.04. Following the transaction, the insider now owns 62,053 shares in the company, valued at approximately $3,797,023.07. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.February 25, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 29,328 SharesSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) CEO Saqib Islam sold 29,328 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $60.30, for a total transaction of $1,768,478.40. Following the completion of the transaction, the chief executive officer now owns 1,034,625 shares of the company's stock, valued at approximately $62,387,887.50. This trade represents a 2.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.February 25, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Sells 47,600 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) Director Daniel Lynch sold 47,600 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $60.22, for a total transaction of $2,866,472.00. Following the sale, the director now owns 82,944 shares of the company's stock, valued at approximately $4,994,887.68. The trade was a 36.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 25, 2025 | marketbeat.comJ.P. Morgan Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)February 25, 2025 | markets.businessinsider.comBhavesh Ashar Sells 1,016 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockFebruary 25, 2025 | insidertrades.comState of New Jersey Common Pension Fund D Increases Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)State of New Jersey Common Pension Fund D increased its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 19.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,343 shareFebruary 24, 2025 | marketbeat.comWedbush Brokers Reduce Earnings Estimates for SWTXSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) - Analysts at Wedbush cut their Q1 2025 EPS estimates for shares of SpringWorks Therapeutics in a research report issued on Thursday, February 20th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per shaFebruary 24, 2025 | marketbeat.comSpringWorks Therapeutics' (SWTX) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday.February 22, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)Principal Financial Group Inc. grew its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 20.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,103,858 shares of the company's stock after acquiringFebruary 22, 2025 | marketbeat.com3SWTX : What the Options Market Tells Us About SpringWorks TherapeuticsFebruary 21, 2025 | benzinga.comSpringWorks Therapeutics price target lowered to $77 from $78 at GuggenheimFebruary 21, 2025 | markets.businessinsider.comSpringWorks Therapeutics (NASDAQ:SWTX) Earns Outperform Rating from WedbushWedbush reiterated an "outperform" rating and set a $81.00 target price on shares of SpringWorks Therapeutics in a research report on Thursday.February 21, 2025 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Announces Earnings Results, Misses Estimates By $0.38 EPSSpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%.February 21, 2025 | marketbeat.comSpringWorks Therapeutics (NASDAQ:SWTX) Sets New 1-Year High - Time to Buy?SpringWorks Therapeutics (NASDAQ:SWTX) Hits New 1-Year High - What's Next?February 21, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. Corproate Presentation - February 2025February 21, 2025 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 21, 2025 | seekingalpha.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch Sells 400 SharesSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) Director Daniel Lynch sold 400 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $60.00, for a total transaction of $24,000.00. Following the completion of the sale, the director now owns 130,544 shares in the company, valued at $7,832,640. The trade was a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.February 20, 2025 | marketbeat.comInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) CEO Sells 10,672 Shares of StockSpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Get Free Report) CEO Saqib Islam sold 10,672 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $59.92, for a total value of $639,466.24. Following the transaction, the chief executive officer now owns 1,063,953 shares of the company's stock, valued at approximately $63,752,063.76. The trade was a 0.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 20, 2025 | marketbeat.comSpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)February 20, 2025 | markets.businessinsider.comSpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors ExpectFebruary 20, 2025 | msn.comWhy SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025February 20, 2025 | msn.com Remove Ads Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Media Mentions By Week SWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SWTX News Sentiment▼0.930.62▲Average Medical News Sentiment SWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SWTX Articles This Week▼75▲SWTX Articles Average Week Remove Ads Get SpringWorks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Ascendis Pharma A/S News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SWTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
